Merck & Co's integrated pipeline has over 20 drugs and vaccines in late-stage development

2 March 2010

Since the recent completion of its $41.1 billion takeover of fellow US drug major Schering-Plough, Merck & Co's integrated new R&D pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development, the group revealed yesterday.

Merck will face the US loss of Cozaar/Hyzaar (losartan) and Temodar (temozolomide) to generic competition in 2010, but the company should also start to see some of the benefits of the Schering-Plough integration, along with hopefully positive news from its late-stage pipeline, analysts at Credit Suisse recently noted, as they upgraded Merck, saying it has the most attractive pipeline in the industry and this view drives their outperform rating on the drugmaker. In fact, also yesterday, Israel-based Teva announced that it had launched a generic version of Cozarar in the USA.

Robust and diversified portfolio

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK